<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Michael S. Wolfe</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>120</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-4606-5198" target="_blank">0000-0003-4606-5198</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Gamma-secretase](/proteins/gamma-secretase), [APP processing](/mechanisms/app-processing), Drug discovery</td>
</tr>
</table>
Michael S. Wolfe
Overview
Michael S. Wolfe is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Texas Southwestern. Their research focuses on Gamma-secretase, [APP](/entities/app-protein) processing, Drug discovery, with particular emphasis on Alzheimer's Disease. With an h-index of 120, Wolfe is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Michael S. Wolfe</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>120</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-4606-5198" target="_blank">0000-0003-4606-5198</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Gamma-secretase](/proteins/gamma-secretase), [APP processing](/mechanisms/app-processing), Drug discovery</td>
</tr>
</table>
Michael S. Wolfe
Overview
Michael S. Wolfe is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Texas Southwestern. Their research focuses on Gamma-secretase, [APP](/entities/app-protein) processing, Drug discovery, with particular emphasis on Alzheimer's Disease. With an h-index of 120, Wolfe is among the most cited researchers in the neuroscience field[@orcid2026].
Wolfe's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Gamma-secretase, APP processing, Drug discovery, publishing in high-impact journals including Nat Rev Drug Discov.
Based at University of Texas Southwestern, Wolfe collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- Gamma-secretase
- [APP processing](/mechanisms/app-processing)
- Drug discovery
Programmatic Emphasis
Wolfe's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Gamma-secretase, APP processing, Drug discovery domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Gamma-secretase as drug target](https://doi.org/10.1038/nrd3300). Nat Rev Drug Discov, 2010.[@gammasecretase2010]
Recent Research
Recent PubMed-indexed publications (2022-present):
[Glucose measurement in cerebrospinal fluid compared to peripheral blood in dogs with central nervous system disease.](https://pubmed.ncbi.nlm.nih.gov/41479422/). Frontiers in veterinary science. 2025.
[Clinical performance of scalable automated p-tau 217 multi-analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay.](https://pubmed.ncbi.nlm.nih.gov/41283139/). Alzheimer's & dementia (Amsterdam, Netherlands). 2025.
[Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology.](https://pubmed.ncbi.nlm.nih.gov/40708958/). Frontiers in neurology. 2025.
[Gray Matter Differences in Adolescent Psychiatric Inpatients: A Machine Learning Study of Bipolar Disorder and Other Psychopathologies.](https://pubmed.ncbi.nlm.nih.gov/40495436/). Brain and behavior. 2025.
[Newborn hearing screening methodology impacts the timing of diagnosis for auditory neuropathy spectrum disorder.](https://pubmed.ncbi.nlm.nih.gov/37207575/). American journal of otolaryngology. 2023.
Collaborators and Research Network
[Dennis J. Selkoe](/researchers/dennis-selkoe)
Institutional Context
Primary institutional links: [University of Texas Southwestern](/university-of-texas-southwestern). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Gamma-secretase, APP processing, Drug discovery signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0003-4606-5198](https://orcid.org/0000-0003-4606-5198)
- Google Scholar: [Search for Michael S. Wolfe](https://scholar.google.com/scholar?q=author%3A%22Michael+S.+Wolfe%22)
- PubMed: [Author search for Michael S. Wolfe](https://pubmed.ncbi.nlm.nih.gov/?term=Michael+S.+Wolfe%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, Gamma-secretase as drug target (2010)](https://doi.org/10.1038/nrd3300)
Unknown, ORCID profile for Michael S. Wolfe (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)